Press Release on the Financial Results of the Company for the quarter and year ended March 31, 2026
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported exceptional Q4FY26 results with total income surging 134.9% year-on-year to Rs. 788.7 crore. EBITDA jumped 448.6% to Rs. 319.4 crore with margins expanding dramatically from 17.3% to 40.5%. Profit after tax grew 666.3% to Rs. 212.5 crore versus Rs. 27.7 crore in Q4FY25. The company attributed performance to strong execution discipline, customer satisfaction, and business fundamentals. Management mentioned good short-to-medium term visibility anchored by commercial molecules, and ongoing investments in peptide manufacturing and a new R&D centre proceeding on schedule.
The stock should react very positively given the dramatic acceleration in revenue and profitability, along with significant margin expansion. The 666% PAT growth and 40%+ EBITDA margins signal strong operational leverage and could attract investor interest in the pharma API manufacturer.